The treatment for acquired reactive perforating collagenosis with abrocitinib: A case report

Reactive perforating collagenosis is a dermatological condition characterized by the transepidermal elimination of collagen. Clinically, it presents as papules with umbilicated hyperkeratosis or dome-shaped lesions featuring a central crater.1 Etiologically, reactive perforating collagenosis can be classified into hereditary and acquired forms. The acquired form, known as acquired reactive perforating collagenosis (ARPC), predominantly affects adults and is frequently associated with intense pruritus and various systemic diseases.